OSLO, Norway, 11 July, 2019 /PRNewswire/ -- Nordic Nanovector
ASA (OSE: NANO) announces that the final patient has been enrolled
in the LYMRIT 37-05 clinical trial of Betalutin®
(177Lu-satetraxetan-lilotomab) in patients with relapsed/refractory
diffuse large B-cell lymphoma (DLBCL) not eligible for stem cell
transplantation.
The LYMRIT 37-05 study is a Phase 1 open-label, single-arm,
dose-escalation study designed to assess the safety, tolerability,
pharmacokinetic profile and preliminary anti-tumour activity of a
single administration of Betalutin®. Patients were enrolled at
clinical trial sites in the US and Europe. More information on this study can be
found at www.clinicaltrials.gov (NCT02658968). Preliminary results
are expected in the second half of 2019.
DLBCL is an aggressive form of non-Hodgkin's Lymphoma (NHL) that
accounts for up to 43% of all NHL cases, making it the most common
form of the disease. Approximately 40% of DLBCL patients relapse
after first-line combination treatment with rituximab and
chemotherapy and only 30-40% of relapsed patients respond with
subsequent high-dose chemotherapy followed by Stem Cell
Transplantation (ref. 1 below). There are currently very few
therapeutic options for patients not eligible for SCT, which makes
relapsed DLBCL a serious unmet medical need. The number of
diagnosed cases of DLBCL in the US and Europe in 2016 was 26,500 and 17,200,
respectively. These numbers are expected to reach 31,500 (US) and
19,000 (Europe) by 2024 (ref. 2
below).
Lisa Rojkjaer, Chief Medical Officer at Nordic Nanovector, said:
"We are delighted to have reached this important milestone and look
forward to the preliminary results during the second half of the
year. Planning is underway for an expansion cohort to further
assess safety and efficacy in this challenging to treat patient
population. We expect more patients to be enrolled when the best
dose is selected from the first part of the study."
References
1. L.S. Raut and P. P. Chakrabarti: Management of
relapsed-refractory diffuse large B cell lymphoma (2014) South
Asian J. Cancer 3(1): 66–70
2. Non-Hodgkin's Lymphoma (2015) Decision Resources
About Nordic Nanovector
Nordic Nanovector is committed to develop and deliver innovative
therapies to patients to address major unmet medical needs and
advance cancer care. The Company aspires to become a leader in the
development of targeted therapies for haematological cancers.
Nordic Nanovector's lead clinical-stage candidate is Betalutin®,
a novel CD37-targeting radioimmunotherapy designed to advance the
treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication
with substantial unmet medical need, representing a growing market
forecast to be worth nearly USD 29
billion by 2026. Nordic Nanovector intends to retain
marketing rights and to actively participate in the
commercialisation of Betalutin® in core markets.
Further information can be found at www.nordicnanovector.com
Forward-looking statements
This press release contains certain forward-looking
statements. These statements are based on management's current
expectations and are subject to uncertainty and changes in
circumstances, since they relate to events and depend on
circumstances that will occur in the future and which, by their
nature, will have an impact on Nordic Nanovector's business,
financial condition and results of operations. The terms
"anticipates", "assumes", "believes", "can", "could", "estimates",
"expects", "forecasts", "intends", "may", "might", "plans",
"should", "projects", "targets", "will", "would" or, in each case,
their negative, or other variations or comparable terminology are
used to identify forward-looking statements. These forward-looking
statements are not historic facts. There are a number of factors
that could cause actual results and developments to differ
materially from those expressed or implied in the forward-looking
statements. Factors that could cause these differences include, but
are not limited to, risks associated with implementation of Nordic
Nanovector's strategy, risks and uncertainties associated with the
development and/or approval of Nordic Nanovector's product
candidates, ongoing and future clinical trials and expected trial
results, the ability to commercialise Betalutin®, technology
changes and new products in Nordic Nanovector's potential market
and industry, Nordic Nanovector's freedom to operate (competitors
patents) in respect of the products it develops, the ability to
develop new products and enhance existing products, the impact of
competition, changes in general economy and industry conditions,
and legislative, regulatory and political factors. No assurance can
be given that such expectations will prove to have been correct.
Nordic Nanovector disclaims any obligation to update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.
This information is subject to a duty of disclosure pursuant
to Section 5-12 of the Securities Trading Act.
CONTACT:
For further information, please contact:
IR enquiries
Malene Brondberg, VP Investor Relations and Corporate
Communications
Cell: +44-7561-431-762
Email: ir@nordicnanovector.com
International Media Enquiries
Mark Swallow/David Dible (Citigate Dewe Rogerson)
Tel: +44-207-638-9571
Email: nordicnanovector@citigatedewerogerson.com
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/nordic-nanovector/r/nordic-nanovector-completes-patient-enrolment-into-phase-1-trial-of-betalutin--in-diffuse-large-b-ce,c2861793